Change in the genotypes of <i>ATM</i>, <i>ERCC1</i>, and <i>XRCC1</i>. by Hao Deng (409186)

“…As CWP progressed, the CC and CA genotypes of <i>ERCC1</i> rs3212986 decreased and increased significantly, respectively. …”

Seven forecast scenarios. by Ryan P. Thombs (9138968)

“…We estimate error correction models, which we ensure are free from residual autocorrelation and structural breaks. We find that a decrease in expenditures has a larger effect on decreasing energy consumption than an increase in expenditures does on increasing consumption. …”

Forecast for each scenario, 2023-2032. by Ryan P. Thombs (9138968)

“…We estimate error correction models, which we ensure are free from residual autocorrelation and structural breaks. We find that a decrease in expenditures has a larger effect on decreasing energy consumption than an increase in expenditures does on increasing consumption. …”

Anxiolytic (N05B) prescribing changes from 2014 to 2022. by Dainty Ei (22265317)

Antidepressant (N06A) prescribing changes from 2014 to 2022. by Dainty Ei (22265317)

Changes in the respiration rates of seeds stored under different conditions. by Junming Zhang (5446787)

DALYs and ASDR of thyroid cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

DALYs and ASDR of larynx cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

DALYs and ASDR of nasopharynx cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

Changes in inflammatory cytokine levels compared with baseline values in all patients over time. by Jia Song (495396)

Distribution of different ingredients at the same IDDSI level (Percentage and frequency) and statistical significance analysis (Chi-square test)^b'*'. by Muxi Chen (9294270)

Subjects:

Changes in sRAGE levels in BALF after 120 consecutive days of CS exposure. by Yue He (385239)

Subjects:

Data. by Su Hwan Park (15158181)

“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”

Control (Ctrl) STZ mice show changes in glomerular morphology. by Andrey V. Cybulsky (4007012)

Baseline characteristics of patients. by Su Hwan Park (15158181)

“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”

Changes in bacterial concentration and monomeric urease activity over time. by Xiaoyan Ding (291429)

HFD changes lysosomal activity. by Tong Yue (6033305)

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Changes in continuous sleep measures from pre (t1) to post (t2) intervention. by Anton Kurapov (11346019)